Skip to main content
. 2015 Sep 23;29(10):847–863. doi: 10.1007/s40263-015-0281-8
Most of the phase III trials on antiepileptic drugs (AEDs) conducted to date have major methodological limitations, preventing meaningful conclusions on comparative efficacy between old and new AEDs in children.
The superiority of the new AEDs in terms of efficacy has only been tested versus placebo.
The commonly held opinion that new and newer AEDs have a better safety profile than old ones does not appear to be supported by evidence.